PFM Health Sciences’s Johnson & Johnson JNJ Stock Holding History

PFM Health Sciences’s Portfolio JNJ Stock Details JNJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-450,000	Closed	-$79.5M	–	92
2022 Q4	$79.5M	Buy	+450,000	New	+$77.7M	2.85%	9

Other funds holding JNJ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PFM Health Sciences's JNJ Position: Q3 2024 in Review

PFM Health Sciences sold out of Johnson & Johnson (JNJ) in Q3 2024, closing a stake of 128,825 shares — an estimated $18.8M sold.

PFM Health Sciences first reported a position in JNJ in Q1 2020 and held it in 8 quarters. The position peaked at $109M in Q2 2022. 3,881 funds tracked by Wall St. Rank hold JNJ as of Q3 2024.

PFM Health Sciences reported no remaining Johnson & Johnson position as of Q3 2024 after selling out during the quarter.
PFM Health Sciences sold 128,825 Johnson & Johnson shares in Q3 2024, an estimated $18.8M.
PFM Health Sciences first reported a position in Johnson & Johnson in Q1 2020 and held it in 8 quarters.
PFM Health Sciences's Johnson & Johnson position peaked at $109M in Q2 2022.
3,881 funds tracked by Wall St. Rank held Johnson & Johnson as of Q3 2024.

Based on PFM Health Sciences's 13F filing for Q3 2024, filed 14 Nov 2024.